Sclerothrapy of giant lymphatic malformation in neonates.

IF 2.4 3区医学 Q2 OBSTETRICS & GYNECOLOGY Journal of Perinatology Pub Date : 2024-09-23 DOI:10.1038/s41372-024-02113-z

Fan Hu, Fan Ma, Xiaoliang Liu, Jiayun Yu

{"title":"Sclerothrapy of giant lymphatic malformation in neonates.","authors":"Fan Hu, Fan Ma, Xiaoliang Liu, Jiayun Yu","doi":"10.1038/s41372-024-02113-z","DOIUrl":null,"url":null,"abstract":"Objective: To analyze the sclerotherapy of giant (≥8 mm) lymphatic malformations in neonates and discuss effective treatment.Methods: This was a single-center retrospective study. Twelve patients received bleomycin (BLM) (six patients) or BLM combined with polidocanol (POL) (eight patients). The safety and effects of BLM and BLM + POL were analyzed using a t-test for categorical data and likelihood ratios or Fisher's exact test for continuous data. Factors resulting in an increased number of treatment sessions were studied.Results: Treatment began 2-5 days after birth. The patients in the BLM group underwent more treatment sessions. Gestational age, lesion size and type, total response, and complications showed no significant differences between groups. Larger and mixed-ype lesions required more treatment sessions.Conclusions: Both BLM group and BLM + POL group appear relatively safe and effective in neonates with giant lymphatic malformations. The combination of the two agents reduced the number of procedures and general anesthesia required.","PeriodicalId":16690,"journal":{"name":"Journal of Perinatology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Perinatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41372-024-02113-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: To analyze the sclerotherapy of giant (≥8 mm) lymphatic malformations in neonates and discuss effective treatment.

Methods: This was a single-center retrospective study. Twelve patients received bleomycin (BLM) (six patients) or BLM combined with polidocanol (POL) (eight patients). The safety and effects of BLM and BLM + POL were analyzed using a t-test for categorical data and likelihood ratios or Fisher's exact test for continuous data. Factors resulting in an increased number of treatment sessions were studied.

Results: Treatment began 2-5 days after birth. The patients in the BLM group underwent more treatment sessions. Gestational age, lesion size and type, total response, and complications showed no significant differences between groups. Larger and mixed-ype lesions required more treatment sessions.

Conclusions: Both BLM group and BLM + POL group appear relatively safe and effective in neonates with giant lymphatic malformations. The combination of the two agents reduced the number of procedures and general anesthesia required.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新生儿巨大淋巴畸形的硬化剂治疗。

目的分析新生儿巨大（≥8 mm）淋巴畸形的硬化剂治疗，并探讨有效的治疗方法：这是一项单中心回顾性研究。12名患者接受了博莱霉素（BLM）（6名）或博莱霉素联合多利多卡诺（POL）（8名）治疗。对分类数据采用t检验，对连续数据采用似然比或费雪精确检验，分析BLM和BLM + POL的安全性和效果。研究了导致治疗次数增加的因素：治疗从出生后 2-5 天开始。BLM组患者接受的治疗次数更多。妊娠年龄、病灶大小和类型、总反应和并发症在各组间无显著差异。较大和混合型病灶需要更多的治疗次数：结论：BLM 组和 BLM + POL 组对患有巨大淋巴畸形的新生儿都相对安全有效。结论：BLM 组和 BLM + POL 组对患有巨大淋巴畸形的新生儿都相对安全有效，两种药物的联合使用减少了治疗次数和所需的全身麻醉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Perinatology 医学-妇产科学

CiteScore

5.40

自引率

6.90%

发文量

284

审稿时长

3-8 weeks

期刊介绍： The Journal of Perinatology provides members of the perinatal/neonatal healthcare team with original information pertinent to improving maternal/fetal and neonatal care. We publish peer-reviewed clinical research articles, state-of-the art reviews, comments, quality improvement reports, and letters to the editor. Articles published in the Journal of Perinatology embrace the full scope of the specialty, including clinical, professional, political, administrative and educational aspects. The Journal also explores legal and ethical issues, neonatal technology and product development. The Journal’s audience includes all those that participate in perinatal/neonatal care, including, but not limited to neonatologists, perinatologists, perinatal epidemiologists, pediatricians and pediatric subspecialists, surgeons, neonatal and perinatal nurses, respiratory therapists, pharmacists, social workers, dieticians, speech and hearing experts, other allied health professionals, as well as subspecialists who participate in patient care including radiologists, laboratory medicine and pathologists.